Other reasons for the specific interest in degarelix is due the fact that this drug is currently approved to treat patients with PCa that need ADT, offering faster and more effective blockage, as well as similar cost-effectiveness and better tolerance compared to GnRH agonists [7,8,35,36]. Here, GNRH1 is linked to posterior cortical atrophy.